Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.73 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.73 |
| ▸ | CNR1 | P21554 | 1/20 | 0.58 |
| ▸ | KDM1A | O60341 | 7/20 | 0.57 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.56 |
| ▸ | MAOB | P27338 | 1/20 | 0.55 |
| ▸ | TLR2 | O60603 | 5/20 | 0.55 |
| ▸ | TLR1 | Q15399 | 5/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.54 |
| ▸ | MAOA | P21397 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6153775 | 1.00 | SMN1; SMN2 (0.73) | SMN1; SMN2NPSR1CNR1KDM1AEPHX2 | |
| SCHEMBL7980208 | 1.00 | SMN1; SMN2 (0.73) | SMN1; SMN2NPSR1CNR1KDM1AEPHX2 | |
| SCHEMBL3457343 | 1.00 | SMN1; SMN2 (0.73) | SMN1; SMN2NPSR1CNR1KDM1AEPHX2 | |
| SCHEMBL2362144 | 0.89 | SMN1; SMN2 (0.60) | SMN1; SMN2NPSR1CNR1KDM1AEPHX2 | |
| SCHEMBL2362145 | 0.89 | SMN1; SMN2 (0.60) | SMN1; SMN2NPSR1CNR1KDM1AEPHX2 | |
| SCHEMBL2776191 | 0.85 | SMN1; SMN2 (0.55) | SMN1; SMN2NPSR1CNR1KDM1AEPHX2 | |
| SCHEMBL2776196 | 0.85 | SMN1; SMN2 (0.55) | SMN1; SMN2NPSR1CNR1KDM1AEPHX2 | |
| SCHEMBL25021708 | 0.85 | SMN1; SMN2 (1.00) | SMN1; SMN2NPSR1CNR1KDM1AEPHX2 | |
| SCHEMBL14544486 | 0.85 | SMN1; SMN2 (1.00) | SMN1; SMN2NPSR1CNR1KDM1AEPHX2 | |
| SCHEMBL13794162 | 0.85 | SMN1; SMN2 (1.00) | SMN1; SMN2NPSR1CNR1KDM1AEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1579864-A1 | Oxolide antibacterials | ABBOTT LABORATORIES (US) | 2005-09-28 | — | — | EP | claimed |
| EP-1499326-A1 | OXOLIDE ANTIBACTERIALS | Abbott Laboratories (US) | 2005-01-26 | — | — | EP | claimed |
| WO-2003090760-A1 | OXOLIDE ANTIBACTERIALS | ABBOTT LABORATORIES (US) | 2003-11-06 | — | — | WO | claimed |
| WO-2023121992-A1 | CYCLOPROPYL COMPOUNDS | ICAGEN, LLC (US) | 2023-06-29 | — | — | WO | disclosed |
| EP-3736265-A1 | (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | Oryzon Genomics, S.A. (ES) | 2020-11-11 | — | — | EP | disclosed |
| EP-3673906-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | Genzyme Corporation (US) | 2020-07-01 | — | — | EP | disclosed |
| EP-2768805-B1 | (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | ORYZON GENOMICS SA (ES) | 2020-03-25 | — | — | EP | disclosed |
| US-20200048266-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GENZYME CORP (US) | 2020-02-13 | — | — | US | disclosed |
| US-10329256-B2 | (Hetero)aryl cyclopropylamine compounds as LSD1 inhibitors | ORYZON GENOMICS, S.A. (ES) | 2019-06-25 | — | — | US | disclosed |
| US-10202330-B2 | Lysine specific demethylase-1 inhibitors and their use | ORYZON GENOMICS, SA (ES) | 2019-02-12 | — | — | US | disclosed |
| US-20180354902-A1 | (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | ORYZON GENOMICS S.A. (ES) | 2018-12-13 | — | — | US | disclosed |
| US-8722743-B2 | Lysine specific demethylase-1 inhibitors and their use | ORYZON GENOMICS S.A. (ES) | 2014-05-13 | — | — | US | disclosed |
| WO-2013057320-A1 | (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | ORYZON GENOMICS, S.A. (ES) | 2013-04-25 | — | — | WO | disclosed |
| US-20130090386-A1 | LYSINE SPECIFIC DEMETHYLASE-1 INHIBITORS AND THEIR USE | ORYZON GENOMICS S.A. | 2013-04-11 | — | — | US | disclosed |
| EP-2560947-A1 | LYSINE SPECIFIC DEMETHYLASE-1 INHIBITORS AND THEIR USE | Oryzon Genomics, S.A. (ES) | 2013-02-27 | — | — | EP | disclosed |
| EP-2486925-A1 | THERAPEUTIC AGENT FOR CEREBRAL INFARCTION | Mitsubishi Tanabe Pharma Corporation (JP) | 2012-08-15 | — | — | EP | disclosed |
| US-20120196824-A1 | THERAPEUTIC AGENT FOR CEREBRAL INFARCTION | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-08-02 | — | — | US | disclosed |
| EP-1579864-A1 | Oxolide antibacterials | ABBOTT LABORATORIES (US) | 2005-09-28 | — | — | EP | disclosed |
| EP-1499326-A1 | OXOLIDE ANTIBACTERIALS | Abbott Laboratories (US) | 2005-01-26 | — | — | EP | disclosed |
| WO-2003090760-A1 | OXOLIDE ANTIBACTERIALS | ABBOTT LABORATORIES (US) | 2003-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180354902-A1 | (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | KDM1B, KDM1A, KDM2A | SMN1; SMN2 557/4885NPSR1 3133/4885CNR1 396/4885 |
| US-20200048266-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GBA1, GBA2, GAA | SMN1; SMN2 1739/4885NPSR1 1945/4885CNR1 2064/4885 |
| US-20120196824-A1 | THERAPEUTIC AGENT FOR CEREBRAL INFARCTION | FABP7, TIMP3, MMP11 | SMN1; SMN2 345/4885NPSR1 779/4885CNR1 1521/4885 |
| US-10202330-B2 | Lysine specific demethylase-1 inhibitors and their use | KDM1A, KDM1B, KDM3A | SMN1; SMN2 4142/4885NPSR1 3774/4885CNR1 134/4885 |
| US-20130090386-A1 | LYSINE SPECIFIC DEMETHYLASE-1 INHIBITORS AND THEIR USE | KDM1A, KDM1B, KDM3A | SMN1; SMN2 4142/4885NPSR1 3774/4885CNR1 134/4885 |
| US-10329256-B2 | (Hetero)aryl cyclopropylamine compounds as LSD1 inhibitors | KDM1B, KDM1A, KDM2A | SMN1; SMN2 557/4885NPSR1 3133/4885CNR1 396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.